Menu Search
Equities

Henan Taloph Pharmaceutical Stock Co Ltd

600222:SHH

Henan Taloph Pharmaceutical Stock Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)4.27
  • Today's Change-0.05 / -1.16%
  • Shares traded5.13m
  • 1 Year change-19.43%
  • Beta1.3375
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Henan Taloph Pharmaceutical Stock Co Ltd grew revenues 5.57% from 1.96bn to 2.07bn while net income improved from a loss of 72.20m to a gain of 43.56m.
Gross margin28.52%
Net profit margin5.68%
Operating margin5.70%
Return on assets3.25%
Return on equity7.30%
Return on investment7.08%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Henan Taloph Pharmaceutical Stock Co Ltd fell by 79.72m. However, the company earned 43.74m from its operations for a Cash Flow Margin of 2.11%. In addition the company generated 26.56m cash from financing while 150.02m was spent on investing.
Cash flow per share--
Price/Cash flow per share--
Book value per share2.73
Tangible book value per share2.09
More ▼

Balance sheet in CNYView more

Henan Taloph Pharmaceutical Stock Co Ltd has a Debt to Total Capital ratio of 43.12%, a higher figure than the previous year's 8.63%.
Current ratio1.07
Quick ratio0.81
Total debt/total equity0.7817
Total debt/total capital0.4312
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 159.11%.
Div yield(5 year avg)0.09%
Div growth rate (5 year)--
Payout ratio (TTM)0.00%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		223.02
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.